Skip to content
Clinical Trials – home

Technetium (99mTc): A Radioactive Tracer for Medical Imaging

2 / 3
trials open to patients / all trials
3+
Countries

In short

Technetium (99mTc) is a radioactive isotope being studied in clinical trials for its potential to improve breast cancer screening, particularly in women with dense breast tissue. This article explores how Technetium (99mTc) is used in molecular breast imaging (MBI) and sentinel lymph node biopsy procedures, offering new hope for more accurate and early detection of breast cancer.

At a glance

Primary Use
Breast cancer screening and sentinel lymph node detection
Technique
Molecular Breast Imaging (MBI) and sentinel lymph node biopsy
Advantages
Higher sensitivity in dense breast tissue, potential for lower false-positive rates
Dosage
Varies by study: 8 mCi to 20 mCi for MBI, 0.2 - 0.4 mCi for sentinel lymph node biopsy
Administration
Intravenous injection for MBI, periareolar or peritumoural injection for sentinel lymph node biopsy
Ongoing Research
Optimizing radiation dose, comparing effectiveness to traditional mammography

What is Technetium (99mTc)?

Technetium (99mTc) is a radioactive substance used in medical imaging procedures. It's not a medication that treats diseases directly, but rather a tool that helps doctors see what's happening inside your body. The term "99mTc" refers to a specific form of technetium that emits gamma rays, which can be detected by special cameras.

This substance is often used in a form called Technetium (99mTc) sestamibi, which is also known by the brand name Cardiolite. In this form, the technetium is combined with other molecules that help it travel to specific parts of the body.

Uses of Technetium (99mTc)

Technetium (99mTc) is primarily used in a type of medical imaging called nuclear medicine. This involves introducing small amounts of radioactive material into the body to diagnose or treat various conditions. Some of the main uses include:

  • Breast cancer screening: Technetium (99mTc) is used in a procedure called Molecular Breast Imaging (MBI), which can help detect breast cancers, especially in women with dense breast tissue.
  • Locating lymph nodes: It's used to help surgeons find and remove specific lymph nodes (called sentinel lymph nodes) during breast cancer surgery.
  • Heart imaging: Although not mentioned in the provided studies, Technetium (99mTc) sestamibi is commonly used to examine blood flow in the heart.

How is Technetium (99mTc) Administered?

Technetium (99mTc) is typically given as an injection. The exact method can vary depending on the specific procedure:

  • For breast imaging, it may be injected into a vein.
  • For sentinel lymph node procedures, it's often injected near the tumor or around the nipple area (called periareolar or peritumoural injection).

The amount used is very small, typically measured in millicuries (mCi), which is a unit of radioactivity. For example, one study used 8 mCi for breast imaging, while another used 0.2 - 0.4 mCi for lymph node detection.

Technetium (99mTc) in Molecular Breast Imaging

Molecular Breast Imaging (MBI) is a newer technique that uses Technetium (99mTc) to detect breast cancers. Here's how it works:

  1. You receive an injection of Technetium (99mTc) sestamibi.
  2. The substance travels through your bloodstream and tends to accumulate more in cancer cells than in normal cells.
  3. Special cameras detect the gamma rays emitted by the technetium, creating images of your breast tissue.
  4. Areas that show higher concentrations of the technetium may indicate the presence of cancer.

MBI has shown promise in detecting cancers in women with dense breast tissue, where traditional mammograms might miss some tumors. In one study, MBI was able to find additional cancers that weren't seen on mammograms.

Technetium (99mTc) in Sentinel Lymph Node Biopsy

In breast cancer surgery, it's important to check if cancer has spread to nearby lymph nodes. Technetium (99mTc) is used to help locate the first lymph node(s) where cancer is likely to spread, called the sentinel lymph node(s). This procedure is called sentinel lymph node biopsy:

  1. Technetium (99mTc) is injected near the tumor or around the nipple.
  2. It travels through the lymphatic system, just as cancer cells would.
  3. A special device detects the radioactivity, helping the surgeon locate the sentinel lymph node(s).
  4. The surgeon can then remove these specific nodes for testing, rather than removing many lymph nodes unnecessarily.

This technique helps minimize the number of lymph nodes that need to be removed, reducing the risk of complications like lymphedema (swelling in the arm).

Safety Considerations

While the idea of a radioactive substance in your body might sound scary, Technetium (99mTc) is generally considered safe when used properly. The amount of radiation is very small and short-lived. However, as with any medical procedure, there are some considerations:

  • Always inform your doctor if you're pregnant or breastfeeding, as special precautions may be needed.
  • Some people may experience mild side effects like pain at the injection site or allergic reactions, but these are rare.
  • The radiation exposure from these procedures is typically less than what you'd receive from many common X-ray procedures.

Doctors carefully weigh the benefits of using Technetium (99mTc) against any potential risks. If you have concerns, don't hesitate to discuss them with your healthcare provider.

Questions people often ask

Conditions where Technetium (99Mtc) is being studied

Each condition opens its own overview and trial list

Trials with Technetium (99Mtc)

Recruiting trials first

See all 3 →
Quick filters
  • Participants:Adults
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).